INSMINSMED Incvs its industry peers
A metric-by-metric comparison of INSMED Inc against iShares Biotechnology ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INSMThis | $26.8B#4 | — | 35.4x#5 | 44.2x#4 | 66.7%#1 | -39.7%#5 | -205.6%#5 | -168.6%#6 | -163.0%#4 | 3#1 | -15.2%#4 | — |
| REGN | — | 19.2x#2 | — | — | 1.0%#4 | 2.1%#3 | 24.9%#2 | 14.2%#2 | 9.4%#1 | — | — | — |
| NTRA | $49.8B#2 | — | 27.3x#4 | 21.6x#2 | 35.9%#2 | -9.3%#4 | -13.4%#3 | -11.4%#3 | -18.0%#2 | — | 97.3%#2 | — |
| RVMD | $41.9B#3 | — | 16.1x#3 | — | — | -88.5%#6 | — | -43.4%#5 | — | — | 337.7%#1 | — |
| MRNA | $57.8B#1 | — | 8.6x#2 | 29.7x#3 | -39.9%#5 | 20.8%#1 | -158.1%#4 | -41.7%#4 | -54.6%#3 | — | — | — |
| UTHR | $21.4B#5 | 17.9x#1 | 3.3x#1 | 6.7x#1 | 10.6%#3 | 11.7%#2 | 46.9%#1 | 20.9%#1 | — | — | 25.3%#3 | — |
Peer set: top holdings of IBB (iShares Biotechnology ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice